Navigation Links
NicOx Reports First Quarter 2008 Financial Results

eement with NicOx. This agreement grants Pfizer the exclusive right

to apply NicOx' proprietary nitric oxide-donating technology to drug

discovery research across the field of ophthalmology. The most advanced

project under this agreement is focused on nitric oxide-donating

prostaglandin analogs for the treatment of glaucoma and has produced

encouraging results for various compounds in a validated in vivo model

of abnormally high intraocular pressure (IOP), compared to a commonly

used reference drug

-- The Company continued to take the necessary steps to ensure the

successful commercialization of naproxcinod and signed an agreement for

the commercial manufacture of naproxcinod drug substance with the fine

chemical company Archimica. The aim of this agreement is to ensure that

commercial supplies of an appropriate scale will be available to ensure

the successful launch of naproxcinod

-- In January, NicOx announced that Pfizer initiated phase 2 clinical

development for PF-03187207 in Japan. PF-03187207 is an investigational

nitric oxide-donating prostaglandin analog for the treatment of

glaucoma. This dose ranging phase 2 study will recruit 120 patients and

is expected to report results in the third quarter of 2008

-- In May, following the end of the first quarter, NicOx announced the

results of a U.S. phase 2 trial for PF-03187207. This dose ranging

study conducted by Pfizer Inc, compared the safety and efficacy of

PF-03187207 to Xalatan(R) (latanoprost) in patients with primary open

angle glaucoma and ocular hypertension. On the primary endpoint,

PF-03187207 showed a 12% improvement over Xalatan(R) 0.005%, which did

not reach statistical significance, although a statistically

significant advantage over Xalatan(R) 0.005% was observed on a number'/>"/>

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
2. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
3. IRIDEX Reports First Quarter 2008 Financial Results
4. Cardiome Reports First Quarter Results
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. Health Plan Execs Receive Smaller Bonuses as Companies Push Performance-Based Pay, HPW Reports; Hanway Tops Others in Total Compensation
7. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
8. Med-Emerg International Inc. reports improved income from continuing operations
9. NxStage Medical Reports First Quarter 2008 Results
10. MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
11. ULURU Inc. Reports First Quarter 2008 Financial Results
Post Your Comments:
(Date:7/28/2014)... Mitul R. Patel, DDS and concerned ... MGE Management Experts Benefit Dinner May 30, in St. ... Dentists to raise funds for the Improving Youth Literacy ... and Youth Programs across America. The funds raised are ... and audio books to directly tackle illiteracy and help ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release ... The new book, DOC X MD Funny Feelings ... telling style with humor and medical accuracy. The book is ... find answers to those age-old questions that most folks are ... Why do mosquitoes bite some and not others? Why do ...
(Date:7/27/2014)... the leader in compression technology and sports medicine, has expanded ... The wrist support features an adjustable velcro strap and provides ... more commonly referred to as tennis elbow and golfers elbow, ... tendons attached to the outside of the elbow. Although this ... the wrist and fingers turn into a tendon that attaches ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... of hepatitis E virus (HEV) transmission by blood components ... have HEV in their plasma. The findings, published in ... blood components (eg, red cells, platelets, and fresh frozen ... England. , The study retrospectively screened 225 000 ... Oct, 2012 and Sept, 2013 for HEV RNA. 79 ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Roughly 15% of children suffer from migraines, and approximately one-third ... of symptoms that can include weakness, blind spots, and even ... new study soon to be published in The Journal ... children and a heart defect called patent foramen ovale, which ...
... cells in the intestine, which when they mutate can lead ... to combat the effects of those same cancers, the UK ... today. Professor Nick Barker of the Institute of Medical ... identified that the stem cells which are crucial to maintaining ...
... Commons, an initiative of CollabRx, a provider of ... research, announces the publication of a molecular disease ... into molecular subtypes, rather than traditional histological or ... subtype, including specific assays, drugs, and clinical trials. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, March ... U.S. Food and Drug Administration (FDA) is meeting Wednesday and ... used food dyes and attention-deficit/hyperactivity disorder (ADHD), and if so, ... industry against some parents, public watchdog groups and academics who,ve ...
... HealthDay Reporter , WEDNESDAY, March 30 (HealthDay News) -- ... nursing homes, a new study shows. Researchers say the ... lead to improvements in patient care. Nor does it appear ... in terms of fewer lawsuits. "Nursing homes that are ...
... for Maternal-Fetal Medicine (SMFM) weighed in on today,s FDA ... caproate, also known as 17P. This FDA announcement ... and others regarding the costs of the just-released pharmaceutical ... made by KV Pharmaceuticals, is being sold at $1,500 ...
Cached Medicine News:Health News:Attacking bowel cancer on 2 fronts 2Health News:Researchers publish molecular disease model for melanoma 2Health News:Researchers publish molecular disease model for melanoma 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 2Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 4Health News:Lawsuits Aren't Improving Nursing Home Care: Study 2Health News:Lawsuits Aren't Improving Nursing Home Care: Study 3Health News:Lawsuits Aren't Improving Nursing Home Care: Study 4Health News:Society for Maternal-Fetal Medicine commends FDA on makena announcement 2
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... release its second quarter and year-to-date 2014 financial results ... the U.S. financial markets. The earnings press release will ... Company,s website, . Arthur ... Charlotte C. Arnold , Vice President and Chief ...
(Date:7/28/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... Nov. 12 Based on its recent analysis ... & Sullivan presents Fovia, Inc. with the 2009 ... Innovation of the Year. Fovia is being recognized ... platform that offers unrivaled image quality and uncompromised ...
... Corporation (Nasdaq: THOR ), a world leader in ... restore failing hearts, said today that it will webcast ... II Destination Therapy clinical trial that will be presented ... American Heart Association(AHA) Scientific Sessions 2009. , The event ...
Cached Medicine Technology:Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 2Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 3Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 4
... MicroAire Power Assisted Lipoplasty Device uses a 2-mm ... facilitate the movement of the cannula in tissue. ... with more fibrous tissue. That makes the lipoplasty ... will ease your mind to learn that the ...
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
... new term being used today to describe the nature ... that may have been used in silicone implants in ... is not new technology cohesive is simply a ... together nature of the gel. All of Mentor silicone ...
Medicine Products: